Cheilitis Granulomatosa Medication
- Author: Crispian Scully, MD, MRCS, PhD, MDS, CBE, FDSRCS(Eng), FDSRCPS, FFDRCSI, FDSRCSE, FRCPath, FMedSci, FHEA, FUCL, FSB, DSc, DChD, DMed(HC), Dr(HC); Chief Editor: Dirk M Elston, MD more...
None of the agents listed below has been systematically evaluated.
Immunomodulatory agents are tried as follows:
Nonsteroidal anti-inflammatory agents (NSAIDs)
Mast cell stabilizers 
Biologics such as infliximab 
Triamcinolone and dapsone injections 
Antimicrobials are as follows:
Tetracycline (used for anti-inflammatory activity)
Antibiotic treatment of dental abscess - Resulted in remission in anecdotal cases
Intralesional corticosteroid (triamcinolone) injections may reduce swelling. Systemic corticosteroids are rarely indicated and not all cases respond. Clofazimine, dapsone, tacrolimus, thalidomide, or antitumor necrosis factor biologics may be needed. No large randomized, controlled trials have yet been recorded with potential therapies such as tacrolimus, thalidomide, or infliximab.
Therapy must be comprehensive and should cover all likely pathogens in the clinical setting.
Clofazimine inhibits mycobacterial growth, binding preferentially to mycobacterial deoxyribonucleic acid (DNA). It has antimicrobial properties, but the mechanism of action is unknown.
Dapsone is bactericidal and bacteriostatic against mycobacteria. Its mechanism of action is similar to that of sulfonamides in which competitive antagonists of para-aminobenzoic acid (PABA) prevent formation of folic acid, inhibiting bacterial growth.
Penicillin G interferes with the synthesis of cell wall mucopeptide during active multiplication, resulting in bactericidal activity against susceptible microorganisms.
Doxycycline is a broad-spectrum, synthetically derived bacteriostatic antibiotic in the tetracycline class. It is almost completely absorbed, concentrates in bile, and is excreted in urine and feces as a biologically active metabolite in high concentrations.
Doxycycline inhibits protein synthesis and, thus, bacterial growth by binding to 30S and possibly the 50S ribosomal subunits of susceptible bacteria. It may block dissociation of peptidyl t-RNA from ribosomes, causing RNA-dependent protein synthesis to arrest.
Erythromycin covers most potential etiologic agents, including Mycoplasma species. The oral regimen may be insufficient to adequately treat Legionella species, and this agent is less active against Haemophilus influenzae. Although the standard course of treatment is 10 days, treatment until the patient has been afebrile for 3-5 days seems a more rational approach. Erythromycin therapy may result in GI upset, causing some clinicians to prescribe an alternative macrolide or change to a thrice-daily dosing.
Erythromycin is a macrolide that inhibits bacterial growth, possibly by blocking dissociation of peptidyl t-RNA from ribosomes, causing RNA-dependent protein synthesis to arrest.
Mast Cell Stabilizers
Mast cell stabilizers inhibit the degeneration of sensitized mast cells when exposed to specific antigens by inhibiting the release of mediators from the mast cells. These agents block calcium ions from entering the mast cell.
Ketotifen is an H1-receptor antagonist and mast cell stabilizer. This agent inhibits the release of mediators from cells involved in hypersensitivity reactions.
These agents decrease inflammatory responses and systemically interfere with events leading to inflammation.
Sulfapyridine is a competitive antagonist of PABA. Its mechanism of action in linear immunoglobulin-A (IgA) dermatosis is unknown. It is no longer available in the US market. It is available only as an orphan drug.
Sulfasalazine decreases the inflammatory response and systemically inhibits prostaglandin synthesis.
These agents have anti-inflammatory properties and cause profound and varied metabolic effects. In addition, these agents modify the body's immune response to diverse stimuli.
Triamcinolone is used to treat inflammatory dermatosis that is responsive to steroids. It decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing capillary permeability.
These agents inhibit key factors that mediate immune reactions, which, in turn, decrease inflammatory responses.
Azathioprine antagonizes purine metabolism and inhibits the synthesis of DNA, ribonucleic acid (RNA), and proteins. It may decrease the proliferation of immune cells, which results in lower autoimmune activity.
Grave B, McCullough M, Wiesenfeld D. Orofacial granulomatosis--a 20-year review. Oral Dis. 2009 Jan. 15 (1):46-51. [Medline].
Khouri JM, Bohane TD, Day AS. Is orofacial granulomatosis in children a feature of Crohn's disease?. Acta Paediatr. 2005 Apr. 94(4):501-4. [Medline].
Narbutt P, Dziki A. Re: Melkersson-Rosenthal syndrome as an early manifestation of Crohn's disease. Colorectal Dis. 2005 Jul. 7(4):420-1. [Medline].
Scully C, Cochran KM, Russell RI, Ferguson MM, Ghouri MA, Lee FD, et al. Crohn's disease of the mouth: an indicator of intestinal involvement. Gut. 1982 Mar. 23(3):198-201. [Medline].
Critchlow WA, Chang D. Cheilitis granulomatosa: a review. Head Neck Pathol. 2014 Jun. 8 (2):209-13. [Medline].
Lazzerini M, Martelossi S, Cont G, Bersanini C, Ventura G, Fontana M, et al. Orofacial granulomatosis in children: think about Crohn's disease. Dig Liver Dis. 2015 Apr. 47 (4):338-41. [Medline].
Troiano G, Dioguardi M, Giannatempo G, Laino L, Testa NF, Cocchi R, et al. Orofacial granulomatosis: clinical signs of different pathologies. Med Princ Pract. 2015. 24 (2):117-22. [Medline].
Blinder D, Yahatom R, Taicher S. Oral manifestations of sarcoidosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Apr. 83(4):458-61. [Medline].
Girlich C, Bogenrieder T, Palitzsch KD, Schölmerich J, Lock G. Orofacial granulomatosis as initial manifestation of Crohn's disease: a report of two cases. Eur J Gastroenterol Hepatol. 2002 Aug. 14(8):873-6. [Medline].
McCartan BE, Healy CM, McCreary CE, Flint SR, Rogers S, Toner ME. Characteristics of patients with orofacial granulomatosis. Oral Dis. 2011 Oct. 17(7):696-704. [Medline].
Ketabchi S, Massi D, Ficarra G, et al. Expression of protease-activated receptor-1 and -2 in orofacial granulomatosis. Oral Dis. 2007 Jul. 13(4):419-25. [Medline].
Tilakaratne WM, Freysdottir J, Fortune F. Orofacial granulomatosis: review on aetiology and pathogenesis. J Oral Pathol Med. 2008 Apr. 37(4):191-5. [Medline].
Saalman R, Sundell S, Kullberg-Lindh C, Lövsund-Johannesson E, Jontell M. Long-standing oral mucosal lesions in solid organ-transplanted children-a novel clinical entity. Transplantation. 2010. 89:606.
McKenna KE, Walsh MY, Burrows D. The Melkersson-Rosenthal syndrome and food additive hypersensitivity. Br J Dermatol. 1994 Dec. 131(6):921-2. [Medline].
Morales C, Penarrocha M, Bagan JV, Burches E, Pelaez A. Immunological study of Melkersson-Rosenthal syndrome. Lack of response to food additive challenge. Clin Exp Allergy. 1995 Mar. 25(3):260-4. [Medline].
Wong GA, Shear NH. Melkersson-Rosenthal syndrome associated with allergic contact dermatitis from octyl and dodecyl gallates. Contact Dermatitis. 2003 Nov. 49(5):266-7. [Medline].
White A, Nunes C, Escudier M, et al. Improvement in orofacial granulomatosis on a cinnamon- and benzoate-free diet. Inflamm Bowel Dis. 2006 Jun. 12(6):508-14. [Medline].
Khandpur S, Malhotra AK, Khanna N. Melkersson-Rosenthal syndrome with diffuse facial swelling and multiple cranial nerve palsies. J Dermatol. 2006 Jun. 33(6):411-4. [Medline].
Saito T, Hida C, Tsunoda I, Tsukamoto T, Yamamoto T. Melkersson-Rosenthal syndrome: distal facial nerve branch palsies, masseter myopathy and corticosteroid treatment. Fukushima J Med Sci. 1994 Jun. 40(1):39-44. [Medline].
Campbell H, Escudier M, Patel P, et al. Distinguishing orofacial granulomatosis from crohn's disease: two separate disease entities?. Inflamm Bowel Dis. 2011 Oct. 17(10):2109-15. [Medline].
Fitzpatrick L, Healy CM, McCartan BE, Flint SR, McCreary CE, Rogers S. Patch testing for food-associated allergies in orofacial granulomatosis. J Oral Pathol Med. 2011 Jan. 40(1):10-3. [Medline].
Banks T, Gada S. A comprehensive review of current treatments for granulomatous cheilitis. Br J Dermatol. 2012 May. 166 (5):934-7. [Medline].
Campbell HE, Escudier MP, Patel P, Challacombe SJ, Sanderson JD, Lomer MC. Review article: cinnamon- and benzoate-free diet as a primary treatment for orofacial granulomatosis. Aliment Pharmacol Ther. 2011 Oct. 34 (7):687-701. [Medline].
White A, Nunes C, Escudier M, Lomer MC, Barnard K, Shirlaw P, et al. Improvement in orofacial granulomatosis on a cinnamon- and benzoate-free diet. Inflamm Bowel Dis. 2006 Jun. 12 (6):508-14. [Medline].
Campbell H, Escudier MP, Brostoff J, Patel P, Milligan P, Challacombe SJ, et al. Dietary intervention for oral allergy syndrome as a treatment in orofacial granulomatosis: a new approach?. J Oral Pathol Med. 2013 Aug. 42 (7):517-22. [Medline].
Williams PM, Greenberg MS. Management of cheilitis granulomatosa. Oral Surg Oral Med Oral Pathol. 1991 Oct. 72(4):436-9. [Medline].
Kruse-Losler B, Presser D, Metze D, Joos U. Surgical treatment of persistent macrocheilia in patients with Melkersson-Rosenthal syndrome and cheilitis granulomatosa. Arch Dermatol. 2005 Sep. 141(9):1085-91. [Medline].
Tan Z, Zhang Y, Chen W, Gong W, Zhao J, Xu X. Recurrent facial palsy in Melkersson Rosenthal syndrome: total facial nerve decompression is effective to prevent further recurrence. Am J Otolaryngol. 2015 May-Jun. 36 (3):334-7. [Medline].
Saalman R, Mattsson U, Jontell M. Orofacial granulomatosis in childhood-a clinical entity that may indicate Crohn's disease as well as food allergy. Acta Paediatr. 2009 Jul. 98(7):1162-7. [Medline].
Kemmler N, Pfannschmidt N, Strohal R. Orofacial granulomatosis as first manifestation of Crohn's disease: successful treatment of both conditions with a combination of infliximab and dapsone. Acta Derm Venereol. 2012 Jul. 92(4):406-7. [Medline].
Kano Y, Shiohara T, Yagita A, Nagashima M. Treatment of recalcitrant cheilitis granulomatosa with metronidazole. J Am Acad Dermatol. 1992 Oct. 27(4):629-30. [Medline].
Fdez-Freire LR, Serrano Gotarredona A, Bernabeu Wittel J, Pulpillo Ruiz A, Cabrera R, Navarrete Ortega M, et al. Clofazimine as elective treatment for granulomatous cheilitis. J Drugs Dermatol. 2005 May-Jun. 4(3):374-7. [Medline].
Tonkovic-Capin V, Galbraith SS, Rogers RS 3rd, Binion DG, Yancey KB. Cutaneous Crohn's disease mimicking Melkersson-Rosenthal syndrome: treatment with methotrexate. J Eur Acad Dermatol Venereol. 2006 Apr. 20(4):449-52. [Medline].
Barry O, Barry J, Langan S, Murphy M, Fitzgibbon J, Lyons JF. Treatment of granulomatous cheilitis with infliximab. Arch Dermatol. 2005 Sep. 141(9):1080-2. [Medline].
Sobjanek M, Wlodarkiewicz A, Zelazny I, Nowicki R, Michajlowski I, Sokolowska-Wojdylo M. Successful treatment of Melkersson-Rosenthal syndrome with dapsone and triamcinolone injections. J Eur Acad Dermatol Venereol. 2008 Aug. 22(8):1028-9; author reply 1027-8. [Medline].
Hazey MA, Van Norman AJ, Armistead DL. Melkersson-Rosenthal Syndrome with migraine-like headaches treated with minocycline: a case report and review of the literature. W V Med J. 2009 Jan-Feb. 105(1):15-7. [Medline].
Ishiguro E, Hatamochi A, Hamasaki Y, Ishikawa S, Yamazaki S. Successful treatment of granulomatous cheilitis with roxithromycin. J Dermatol. 2008 Sep. 35(9):598-600. [Medline].